今天理了下cart和_老虎社区_美港股上老虎

陆biotech

2021-06-01

今天理了下cart和car-nk 仍觉得这个技术会成为和pd1一样的爆款。且会在五年左右临床获批第一个可用于实体瘤的cart技术。

CART Key Players

AbbVie Inc. ABBV

Adaptimmune Therapeutics PLC. ADAP

Amgen, Inc. AMGN

Atara Biotherapeutics, Inc. ATRA

Autolus Therapeutics PLC. AUTL

Bellicum Pharmaceuticals, Inc. BLCM

BioAtla LLC. BCAB

bluebird bio BLUE

Cellectis CLLS

Fate Therapeutics Inc. FATE

Gilead GILD

Humanigen, Inc. HGEN

Mesoblast, Ltd. MESO

Minerva Biotechnologies Corp. NERV

Mustang Bio, Inc. MBIO

Novartis AG NVS

Pfizer, Inc. PFE

Posedia Therapeutics Inc. PSTX

Precision Biosciences, Inc. DTIL

Sorrento Therapeutics, Inc. SRNE

ZIOPHARM Oncology, Inc. ZIOP

LEGN

GRCL

Allogene Therapeutics ALLO

Celyad SA CYAD

CAR-NK

NKArta NKTX

ImmunityBio inc IBRX

Affimed Tx AFMD

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

每天有新高
2021-06-02
每天有新高
Car-t疗法目前中国走在世界的前列，但存在着很大的缺陷与争议。目前已逐渐地被基因疗法赶超，另外同类药中的靶向药物是其最大的竟争对手，美股中例如居里等公司。
- 每天有新高回复陆biotech:
  有一部分，大部分自身的T细胞都不强大，又容易脱靶，神经毒性比较大。

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":119342975,"tweetId":"119342975","gmtCreate":1622523014597,"gmtModify":1622524083055,"author":{"id":3543094710320172,"authorId":3543094710320172,"authorIdStr":"3543094710320172","name":"陆biotech","avatar":"https://static.tigerbbs.com/7000c4d56768ac2cd99d25062909d653","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":24,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>今天理了下cart和car-nk 仍觉得这个技术会成为和pd1一样的爆款。且会在五年左右临床获批第一个可用于实体瘤的cart技术。CART Key PlayersAbbVie Inc. ABBV Adaptimmune Therapeutics PLC. ADAP Amgen, Inc. AMGN Atara Biotherapeutics, Inc. ATRA Autolus Therapeutics PLC. AUTL Bellicum Pharmaceuticals, Inc. BLCM BioAtla LLC. BCAB bluebird bio BLUE Cellectis CLLS Fate Therapeutics Inc. FATE Gilead GILD Humanigen, Inc. HGEN Mesoblast, Ltd. MESO Minerva Biotechnologies Corp. NERV Mustang Bio, Inc. MBIO Novartis AG NVS Pfizer, Inc. PFE Posedia Therapeutics Inc.&nbsp; PSTX Precision Biosciences, Inc. DTIL Sorrento Therapeutics, Inc. SRNE ZIOPHARM Oncology, Inc. ZIOP LEGN GRCL Allogene Therapeutics ALLO Celyad SA CYAD CAR-NKNKArta NKTX ImmunityBio inc IBRX Affimed Tx AFMD</body></html>","htmlText":"<html><head></head><body>今天理了下cart和car-nk 仍觉得这个技术会成为和pd1一样的爆款。且会在五年左右临床获批第一个可用于实体瘤的cart技术。CART Key PlayersAbbVie Inc. ABBV Adaptimmune Therapeutics PLC. ADAP Amgen, Inc. AMGN Atara Biotherapeutics, Inc. ATRA Autolus Therapeutics PLC. AUTL Bellicum Pharmaceuticals, Inc. BLCM BioAtla LLC. BCAB bluebird bio BLUE Cellectis CLLS Fate Therapeutics Inc. FATE Gilead GILD Humanigen, Inc. HGEN Mesoblast, Ltd. MESO Minerva Biotechnologies Corp. NERV Mustang Bio, Inc. MBIO Novartis AG NVS Pfizer, Inc. PFE Posedia Therapeutics Inc.&nbsp; PSTX Precision Biosciences, Inc. DTIL Sorrento Therapeutics, Inc. SRNE ZIOPHARM Oncology, Inc. ZIOP LEGN GRCL Allogene Therapeutics ALLO Celyad SA CYAD CAR-NKNKArta NKTX ImmunityBio inc IBRX Affimed Tx AFMD</body></html>","text":"今天理了下cart和car-nk 仍觉得这个技术会成为和pd1一样的爆款。且会在五年左右临床获批第一个可用于实体瘤的cart技术。 CART Key Players AbbVie Inc. ABBV Adaptimmune Therapeutics PLC. ADAP Amgen, Inc. AMGN Atara Biotherapeutics, Inc. ATRA Autolus Therapeutics PLC. AUTL Bellicum Pharmaceuticals, Inc. BLCM BioAtla LLC. BCAB bluebird bio BLUE Cellectis CLLS Fate Therapeutics Inc. FATE Gilead GILD Humanigen, Inc. HGEN Mesoblast, Ltd. MESO Minerva Biotechnologies Corp. NERV Mustang Bio, Inc. MBIO Novartis AG NVS Pfizer, Inc. PFE Posedia Therapeutics Inc. PSTX Precision Biosciences, Inc. DTIL Sorrento Therapeutics, Inc. SRNE ZIOPHARM Oncology, Inc. ZIOP LEGN GRCL Allogene Therapeutics ALLO Celyad SA CYAD CAR-NK NKArta NKTX ImmunityBio inc IBRX Affimed Tx AFMD","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":2,"favoriteSize":0,"link":"https://laohu8.com/post/119342975","repostId":0,"isVote":1,"tweetType":1,"viewCount":6210,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["CRCT","VIRI","HGEN","CYAD","PLC","CLYYF","TERN","FATE","BLCM","HGEND","ZI","PFE","AUTL","NVSEF","BCAB","MBIO","ATRA"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":661,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":4539064,"gmtCreate":1622597406234,"gmtModify":1622597406234,"authorId":3563871956693501,"author":{"id":3563871956693501,"authorId":3563871956693501,"name":"每天有新高","avatar":"https://static.tigerbbs.com/872fc34821e8b13224b0d415b62b08ab","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":119342975,"type":1,"supId":0,"prevId":0,"content":"Car-t疗法目前中国走在世界的前列，但存在着很大的缺陷与争议。目前已逐渐地被基因疗法赶超，另外同类药中的靶向药物是其最大的竟争对手，美股中例如居里等公司。","text":"Car-t疗法目前中国走在世界的前列，但存在着很大的缺陷与争议。目前已逐渐地被基因疗法赶超，另外同类药中的靶向药物是其最大的竟争对手，美股中例如居里等公司。","html":"Car-t疗法目前中国走在世界的前列，但存在着很大的缺陷与争议。目前已逐渐地被基因疗法赶超，另外同类药中的靶向药物是其最大的竟争对手，美股中例如居里等公司。","likeSize":0,"commentSize":1,"subComments":[{"id":4547431,"gmtCreate":1622642232385,"gmtModify":1622642232385,"authorId":3563871956693501,"author":{"id":3563871956693501,"authorId":3563871956693501,"name":"每天有新高","avatar":"https://static.tigerbbs.com/872fc34821e8b13224b0d415b62b08ab","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3543094710320172,"repliedAuthor":{"id":3543094710320172,"authorId":3543094710320172,"name":"陆biotech","avatar":"https://static.tigerbbs.com/7000c4d56768ac2cd99d25062909d653","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":119342975,"type":1,"supId":4539064,"prevId":4541535,"content":"有一部分，大部分自身的T细胞都不强大，又容易脱靶，神经毒性比较大。","text":"有一部分，大部分自身的T细胞都不强大，又容易脱靶，神经毒性比较大。","html":"有一部分，大部分自身的T细胞都不强大，又容易脱靶，神经毒性比较大。"}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/119342975"}